Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Vaccines|August 29, 2024
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the CongoEdward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, et al.
Plos Medicine|January 23, 2015
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysisCharles S Morrison, Pai-Lien Chen, Cynthia Kwok, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2023
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and AdultsAndrew W Lee, Ken Liu, Edouard Lhomme, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trialDavid Ishola, Daniela Manno, Muhammed O Afolabi, et al.
The Lancet. Infectious Diseases|October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trialDaniela Manno, Agnes Bangura, Frank Baiden, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trialMuhammed O Afolabi, David Ishola, Daniela Manno, et al.
The New England Journal of Medicine|December 14, 2022
Randomized Trial of Vaccines for Zaire Ebola Virus Disease, Mark Kieh, Laura Richert, et al.
Lancet (London, England)|June 11, 2013
Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysisJoanne Katz, Anne Cc Lee, Naoko Kozuki, et al.
Vaccines|August 29, 2024
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the CongoHugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus DiseaseAbdoul Habib Beavogui, Seydou Doumbia, Mark Kieh, et al.
Pageof 15